cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents' purification technologies are based on biocompatible, highly porous polymer beads
Company profile
Ticker
CTSO
Exchange
Website
CEO
Phillip Chan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GILDER ENTERPRISES INC, MedaSorb Technologies CORP
SEC CIK
Corporate docs
Subsidiaries
CytoSorbents Medical Inc. • CytoSorbents Europe GmbH • CytoSorbents Medical UK Limited • United Kingdom and Republic of Ireland • CytoSorbents France SAS • CytoSorbents UK Limited • CytoSorbents India Private Limited ...
IRS number
980373793
CTSO stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
19 Apr 24
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
8-K
Departure of Directors or Certain Officers
3 Apr 24
8-K
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
17 Jan 24
8-K
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
28 Dec 23
8-K
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
13 Dec 23
424B5
Prospectus supplement for primary offering
11 Dec 23
Transcripts
CTSO
Earnings call transcript
2023 Q4
14 Mar 24
CTSO
Earnings call transcript
2023 Q3
9 Nov 23
CTSO
Earnings call transcript
2023 Q2
1 Aug 23
CTSO
Earnings call transcript
2023 Q1
2 May 23
CTSO
Earnings call transcript
2022 Q4
9 Mar 23
CTSO
Earnings call transcript
2022 Q3
3 Nov 22
CTSO
Earnings call transcript
2022 Q2
3 Aug 22
CTSO
Earnings call transcript
2022 Q1
7 May 22
CTSO
Earnings call transcript
2021 Q4
9 Mar 22
CTSO
Earnings call transcript
2021 Q3
7 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.05 mm | 10.05 mm | 10.05 mm | 10.05 mm | 10.05 mm | 10.05 mm |
Cash burn (monthly) | 1.60 mm | 1.18 mm | 3.06 mm | 2.50 mm | 1.74 mm | 1.72 mm |
Cash used (since last report) | 10.84 mm | 8.03 mm | 20.80 mm | 16.97 mm | 11.78 mm | 11.64 mm |
Cash remaining | -795.86 k | 2.02 mm | -10.75 mm | -6.92 mm | -1.73 mm | -1.60 mm |
Runway (months of cash) | -0.5 | 1.7 | -3.5 | -2.8 | -1.0 | -0.9 |
Institutional ownership, Q3 2023
28.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 52 |
Opened positions | 8 |
Closed positions | 12 |
Increased positions | 11 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 28.31 bn |
Total shares | 15.19 mm |
Total puts | 2.10 k |
Total calls | 2.20 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Skylands Capital | 2.94 mm | $5.54 bn |
Avenir | 2.72 mm | $5.11 bn |
Vanguard | 1.95 mm | $3.67 bn |
Granahan Investment Management | 1.55 mm | $2.92 bn |
Neuberger Berman | 1.50 mm | $2.82 bn |
Sargent Investment | 1.26 mm | $2.36 bn |
BLK Blackrock | 726.76 k | $1.37 bn |
CM Management | 450.00 k | $846.00 mm |
Geode Capital Management | 364.92 k | $686.23 mm |
Jacob Asset Management Of New York | 197.94 k | $372.13 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Phillip P. Chan | Common Stock | Grant | Acquire A | No | No | 0 | 96,000 | 0.00 | 1,164,704 |
2 Apr 24 | Phillip P. Chan | Stock Option Common Stock | Grant | Acquire A | No | No | 0.955 | 124,000 | 118.42 k | 124,000 |
2 Apr 24 | Kathleen P. Bloch | Common Stock | Grant | Acquire A | No | No | 0 | 65,000 | 0.00 | 532,941 |
2 Apr 24 | Kathleen P. Bloch | Stock Option Common Stock | Grant | Acquire A | No | No | 0.955 | 87,000 | 83.09 k | 87,000 |
2 Apr 24 | Michael G. Bator | Stock Option Common Stock | Grant | Acquire A | No | No | 0.955 | 44,000 | 42.02 k | 44,000 |
2 Apr 24 | Vincent Capponi | Common Stock | Grant | Acquire A | No | No | 0 | 81,000 | 0.00 | 665,134 |
2 Apr 24 | Vincent Capponi | Stock Option Common Stock | Grant | Acquire A | No | No | 0.955 | 101,000 | 96.46 k | 101,000 |
2 Apr 24 | Jiny Kim | Stock Option Common Stock | Grant | Acquire A | No | No | 0.955 | 22,000 | 21.01 k | 22,000 |
News
HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target
15 Mar 24
Recap: CytoSorbents Q4 Earnings
14 Mar 24
CytoSorbents Q4 2023 GAAP EPS $(0.12) Beats $(0.14) Estimate, Sales $8.700M Miss $9.285M Estimate
14 Mar 24
Earnings Scheduled For March 14, 2024
14 Mar 24
A Preview Of CytoSorbents's Earnings
13 Mar 24
Press releases
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
17 Apr 24
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
14 Mar 24
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
6 Mar 24
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
8 Feb 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
30 Jan 24